$142.94
+5.3%Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
BLTE • NASDAQ
| Belite Bio, Inc Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-77.6M | -36.1M | -31.6M | -12.6M | -9.7M | -5.8M | |
464K | 449K | 399K | 198K | 30K | 17K | |
0.0 | 0.0 | -4.7M | -1.9M | 0.0 | -1.4M | |
38.9M | 9M | 3.8M | 1.5M | 1.5M | 1.4M | |
-1.3M | -3.7M | 4.7M | 1.9M | -8K | 1.4M | |
(0.0) | (6K) | (9K) | (0.0) | (0.0) | (0.0) | |
2.6M | 1.1M | -2.4M | -491K | 640K | -69K | |
-37M | -29.2M | -29.8M | -11.5M | -7.5M | -4.4M | |
INVESTING ACTIVITIES | ||||||
-178K | -116K | -63K | -394K | -74K | -20K | |
(0.0) | (0.0) | (0.0) | (0.0) | (18K) | (0.0) | |
-452M | -188.3M | (0.0) | (0.0) | (0.0) | (0.0) | |
147.1M | 77.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | -35K | 0.0 | 0.0 | 0.0 | 0.0 | |
-305.1M | -110.6M | -63K | -394K | -56K | -20K | |
FINANCING ACTIVITIES | ||||||
292.9M | 42.2M | 77.2M | 38M | -583K | 500K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.3M | |
370.4M | 41.4M | -1.2M | -1M | 0.0 | 86K | |
663.2M | 83.6M | 76M | 37M | -583K | 28.1M | |
CASH FLOW SUMMARY | ||||||
117K | -269K | 9K | -366K | -161K | 4K | |
321.3M | -56.5M | 46.1M | 24.7M | -8.3M | 23.6M | |
31.7M | 88.2M | 42.1M | 17.3M | 25.6M | 2M | |
352.9M | 31.7M | 88.2M | 42.1M | 17.3M | 25.6M | |
-37.2M | -29.4M | -29.9M | -11.9M | -7.5M | -4.5M |
BLTE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
6-K 6-K 2026 Q2 Q2 | May 20, 2026 | May 20, 2026 | 2026 | |
6-K 6-K 2026 Q2 Q2 | April 21, 2026 | April 21, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | March 31, 2026 | March 31, 2026 | 2026 | |
20-F 20-F 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
6-K 6-K 2026 Q1 Q1 | March 02, 2026 | March 02, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | January 27, 2026 | January 27, 2026 | 2026 | |
6-K 6-K 2025 Q4 Q4 | December 02, 2025 | December 02, 2025 | 2025 | |
6-K 6-K 2025 Q4 Q4 | December 01, 2025 | December 01, 2025 | 2025 | |
6-K 6-K 2025 Q4 Q4 | December 01, 2025 | December 01, 2025 | 2025 | |
6-K 6-K 2025 Q4 Q4 | December 01, 2025 | December 01, 2025 | 2025 |
Continue your BLTE research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.